News | October 18, 2023
Syngene Q2 FY23-24 revenue from operations up 18.5% to Rs 910 Cr
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
The approval adds to a list of products that Strides has approved in this therapeutic category through the PEPFAR pathway taking the total to 15 products
The product is bioequivalent and therapeutically equivalent to the RLD, Vascepa of Amarin
Post-acquisition of the balance 25% outstanding shares will result into Sun Pharma de México, S.A. de C.V. becoming a wholly-owned subsidiary of the company.
National Health Authority (NHA) to host the two-day Arogya Manthan event in New Delhi
The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD)
Prior to this, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
Subscribe To Our Newsletter & Stay Updated
